Business Wire

CA-VERACODE

1.5.2024 14:51:32 CEST | Business Wire | Press release

Share
Veracode Elevates Developer-Powered Application Risk Management with Latest Innovations: Enhanced Repo Risk Visibility & Analysis and Veracode Fix in the IDE

Veracode, a global leader in application risk management, today announced platform innovations that set a new standard for developer-powered application security. New repo risk visibility and analysis from Longbow Security, powered by Veracode, speeds up remediation of application risk from code repositories to runtime images. The solution launches alongside Veracode Fix in the Integrated Development Environment (IDE) and Batch Fix to bridge the gap between development and security teams. These latest innovations help developers focus on the most critical tasks that drive value and differentiation.

“Developers today face significant competing pressures to innovate faster and perform more security checks on their code than ever before,” said Tim Jarrett, Group Head of Product Management at Veracode. “We are committed to a frictionless experience for developers and security operators and our latest product enhancements make the job of securing code simple and seamless.”

Bringing Developer & Security Teams Together: Repo Risk Visibility & Analysis

In April, Veracode acquired Longbow Security to help organizations effectively manage and reduce application risk across the growing attack surface. The integration of Longbow’s newest capability, repo risk visibility and analysis, bridges the gap between development and security teams with enhanced visibility from code repositories to cloud assets and runtime images. It also illuminates infrastructure-as-code and misconfiguration risk for cloud assets originating from repositories.

“Customers challenged us to apply our unique cloud risk and prioritization expertise from Longbow to problems they face managing upstream risk in their code repositories,” said Derek Maki, Vice President of Product Management at Veracode. “We responded with a solution that gives visibility into the relationship between source code weaknesses and runtime security posture. Simultaneously, development teams get a consolidated view of risk and huge time savings when it comes to prioritizing remediation, reducing code changes, and fixing issues fast.”

This new feature complements Veracode’s latest innovation for GitHub repo scanning, which enables developers to streamline activities like staging servers and environments so they don’t need to scan every time. This makes it easier for development and security teams to collaborate on secure coding and scanning as Veracode results are delivered to GitHub where developers can act immediately.

Security Debt Reduction: Veracode Fix in the IDE & Batch Fix

Research shows 92 percent of U.S.-based developers are already using artificial intelligence (AI) coding tools both in and outside of work, with generative AI helping software engineers write code 35-45 percent faster. At the same time, other research suggests code developed by AI contains the same percentage of security flaws as that generated by humans.

Veracode was the first company to deliver a solution that provides developers with AI-generated secure code fixes. Since launching Veracode Fix at RSA Conference last year, hundreds of customers have used the solution to reduce their backlog of security debt and risk. Ninety-two percent of CWEs (Common Weakness Enumeration) with a severity rating from medium to very high can be addressed through AI-generated code edits from Veracode Fix.

With the introduction of Veracode Fix in the IDE, developers can now fix flaws faster with AI-suggested remediation right in the IDE, without switching applications or researching alternative code options. Fixes can be made before code is pushed through the software development lifecycle, dramatically cutting the time and cost spent fixing flaws compared to retroactive remediation.

Batch Fix enables bulk AI-assisted remediation of flaws in source code across multiple flaws and files in one operation. This makes remediation of flaws an order of magnitude faster, aiding the reduction of security debt at scale. For example, developers can use it to fix a CWE that requires an easy-to-test resolution and run it across multiple source files at once.

Jarrett closed, “With these latest innovations, Veracode meets developers where they are—in the tools they use daily—to help them secure the code they create today, without compromising productivity. This vastly improves efficiency and velocity, fostering a culture of collaboration and trust between development and security teams.”

Repo Risk Visibility & Analysis, Veracode Fix in the IDE, and Batch Fix are available immediately. For more information, please visit the Veracode blog.

Visitors to RSA Conference can learn more about Veracode’s platform and these new features by visiting Veracode’s booth #2045 in the main hall.

About Veracode

Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, and Penetration Testing.

Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and Twitter.

Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240501107223/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release

Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye